Advertisement
UK markets close in 23 minutes
  • FTSE 100

    7,813.94
    -151.59 (-1.90%)
     
  • FTSE 250

    19,353.64
    -345.25 (-1.75%)
     
  • AIM

    739.30
    -10.98 (-1.46%)
     
  • GBP/EUR

    1.1699
    -0.0012 (-0.10%)
     
  • GBP/USD

    1.2446
    -0.0000 (-0.00%)
     
  • Bitcoin GBP

    50,064.39
    -1,686.61 (-3.26%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,051.50
    -10.32 (-0.20%)
     
  • DOW

    37,805.22
    +70.11 (+0.19%)
     
  • CRUDE OIL

    85.57
    +0.16 (+0.19%)
     
  • GOLD FUTURES

    2,397.10
    +14.10 (+0.59%)
     
  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     
  • HANG SENG

    16,248.97
    -351.49 (-2.12%)
     
  • DAX

    17,733.02
    -293.56 (-1.63%)
     
  • CAC 40

    7,915.58
    -129.53 (-1.61%)
     

Inside Novartis’s Ophthalmology Drugs Now

In 3Q17, Novartis's (NVS) Lucentis generated revenues of ~$481 million, which was ~5% higher YoY (year-over-year) and 1% higher QoQ (quarter-over-quarter).